[

serum institute of india news

]
PAGE 2

Latest from serum institute of india

News updates from HT: IMD says monsoon revival unlikely before July 7

Here are today’s top news, analysis, and opinion at this hour. Know all about the latest news and other news updates from Hindustan Times.

Monsoon is unlikely to progress over the rest of northwest India till July 7, India Meteorological Department (IMD) said on Wednesday.(HT Photo)
Monsoon is unlikely to progress over the rest of northwest India till July 7, India Meteorological Department (IMD) said on Wednesday.(HT Photo)
Published on Jul 01, 2021 08:50 AM IST

Jolt to Serum Institute as govt panel says no to Covovax trial on children

The clinical trials of Covovax began in India in March. But the Subject Expert Committee of the Central Drugs Standard Control Organisation denied the approval for its trial on children noting that the vaccine has not been approved in any country.

Covovax is being produced by Serum Institute of India.(HT Photo)
Covovax is being produced by Serum Institute of India.(HT Photo)
Published on Jul 01, 2021 07:01 AM IST

SII applies for EU ‘green pass’ nod through UK partner

The Green Pass is an immunity document meant to ease travel within and to the European Union from July 1. “The EMA certification has been applied for by SII via its partner AstraZeneca,” said an industry insider familiar with the matter, on condition of anonymity.

A day earlier, EU had said in a statement that EMA has not received any authorisation request for Covishield.(File Photo)
A day earlier, EU had said in a statement that EMA has not received any authorisation request for Covishield.(File Photo)
Updated on Jul 01, 2021 06:16 AM IST

SII says working on Covishield EU pass

Indian officials said it was “perplexing” that the list includes Vaxzevria, the AstraZeneca vaccine produced and marketed in the UK and other sites around Europe, but not Covishield, the version manufactured and distributed in India, though they are similar if not identical.

The Covishield vaccine “does not currently have a marketing authorisation” in Europe and the matter would be considered when an application is received for it, the EMA said.(AFP )
The Covishield vaccine “does not currently have a marketing authorisation” in Europe and the matter would be considered when an application is received for it, the EMA said.(AFP )
Updated on Jun 29, 2021 04:41 AM IST

‘Great potential’: Serum Institute begins production of 1st Covovax batch

US biotechnology company Novavax’s protein-based vaccine, NVX-CoV2373, has demonstrated 100% protection against moderate and severe disease, and 90.4% overall efficacy, in its Phase 3 trial.

"Excited to witness the first batch of Covovax (developed by @Novavax) being manufactured this week at our facility in Pune," SII CEO Adar Poonawalla tweeted.(Reuters)
Published on Jun 26, 2021 04:27 AM IST

Serum Institute of India likely to start Covovax trials on kids by July

The trials could start by July, one of the people added on the condition of anonymity.

SII’s CEO Adar Poonawalla had earlier said that the vaccine could be launched in India by September, subject to the grant of necessary regulatory clearances.(Reuters photo)
SII’s CEO Adar Poonawalla had earlier said that the vaccine could be launched in India by September, subject to the grant of necessary regulatory clearances.(Reuters photo)
Published on Jun 18, 2021 05:26 AM IST

Biological E’s vaccine efficacy same as Novavax: Government panel chief

Earlier this month, the Union health ministry announced that it had finalised arrangements with the Hyderabad-based vaccine manufacturer to reserve 300 million doses

On Monday, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based Covid-19 vaccine
On Monday, Novavax announced that NVX-CoV2373, its recombinant nanoparticle protein-based Covid-19 vaccine
Updated on Jun 18, 2021 07:00 AM IST

SII to introduce Novavax vaccine in India by September: Report

Novavax vaccine has shown strong efficacy against the emerging variants of Covid-19 in a large trial, the biotech firm said on June 14.

Novavax showed 93% effectiveness against variants of concern based on test results from a secondary analysis which mostly consisted of cases of the alpha variant which is predominant in the United States.(REUTERS)
Novavax showed 93% effectiveness against variants of concern based on test results from a secondary analysis which mostly consisted of cases of the alpha variant which is predominant in the United States.(REUTERS)
Published on Jun 17, 2021 05:01 PM IST

Shortage of raw material holding up Covovax manufacturing

The delay in receiving raw materials such as bioreactor bags and enzymes means that SII’s launch of the Novavax vaccine, branded as Covovax in India, will not likely happen before September this year as planned originally

SII is the manufacturing partner for Novavax in India(REUTERS)
SII is the manufacturing partner for Novavax in India(REUTERS)
Updated on Jun 17, 2021 07:55 AM IST

SII gets DCGI’s nod to manufacture Sputnik

Sputnik V is currently being distributed in India by Dr Reddy’s Laboratories, which signed a pact with the Russian Direct Investment Fund (RDIF), which globally markets the Covid-19 vaccine developed by Russia’s Gamaleya Institute.

Vials of Russia's Sputnik V COVID-19 vaccine seen at an airport in Republic of San Marino. (REUTERS)
Vials of Russia's Sputnik V COVID-19 vaccine seen at an airport in Republic of San Marino. (REUTERS)
Updated on Jun 05, 2021 03:48 AM IST

News updates from HT: Maharashtra records 14,152 new cases of Covid-19 in 24 hrs

Here are today’s top news, analysis, and opinion. Know all about the latest news and other news updates from Hindustan Times.

Maharashtra reported 14,152 new cases of coronavirus disease (Covid-19) in the last 24 hours (Photo by Satish Bate/Hindustan Times)
Maharashtra reported 14,152 new cases of coronavirus disease (Covid-19) in the last 24 hours (Photo by Satish Bate/Hindustan Times)
Published on Jun 04, 2021 09:32 PM IST

DCGI allows Serum Institute to manufacture Sputnik V vaccine in India

The Pune-based SII has collaborated with Gamaleya Research Institute of Epidemiology and Microbiology, Moscow, in Russia for developing Sputnik V at its licensed Hadapsar facility.

A health worker prepares a dose of the Sputnik V vaccine against Covid-19 (Representational Image / AFP)
A health worker prepares a dose of the Sputnik V vaccine against Covid-19 (Representational Image / AFP)
Published on Jun 04, 2021 09:10 PM IST

Serum Institute of India applies to DCGI to manufacture Covid vaccine Sputnik V

Sputnik V is the third Covid-19 vaccine to be approved by India's drugs regulator DCGI after Bharat Biotech's Covaxin and Covishield, which is manufactured by Serum Institute of India (SII).

A medical worker holds a box of Sputnik V vaccine against the coronavirus disease (Covid-19) in Moscow.(Reuters File Photo)
A medical worker holds a box of Sputnik V vaccine against the coronavirus disease (Covid-19) in Moscow.(Reuters File Photo)
Published on Jun 03, 2021 12:18 PM IST

Can manufacture, supply 90-100 million Covishield doses in June: SII to govt

SII informed the Centre earlier in May that the production of Covishield would be ramped up to 65 million in June, 70 million in July and 100 million each in August and September.

A nurse displays a vial of Covishield, the Covid-19 vaccine being manufactured by the Serum Institute of India, at a medical centre in Mumbai. (File Photo)
A nurse displays a vial of Covishield, the Covid-19 vaccine being manufactured by the Serum Institute of India, at a medical centre in Mumbai. (File Photo)
Published on May 30, 2021 06:17 PM IST

Centre creating 'artificial scarcity' to favour SII, Bharat Biotech, says AAP

AAP spokesperson Atishi claimed that neither Bharat Biotech nor SII possesses the capacity to mass manufacture the required number of vaccine doses to inoculate the entire population of the country.

"The Centre created such an artificial scarcity that states have to buy from them only. The Centre should respond to this," said AAP leader Atishi(Screengrab)
Published on May 28, 2021 04:56 PM IST

Serum Institute of India begins production of Covovax vaccine

US biotechnology company Novavax’s protein-based Covid-19 vaccine, NVX-CoV2373, is being locally manufactured by SII under the brand name Covovax.

The company is already locally producing the Covishield vaccine developed by Oxford University and AstraZeneca.(AP)
The company is already locally producing the Covishield vaccine developed by Oxford University and AstraZeneca.(AP)
Published on May 27, 2021 02:47 AM IST

‘Daily cases were at an all-time low’: Poonawalla defends India’s vaccine export

Serum Institute of India (SII) CEO Adar Poonawalla said the company exported Covid-19 vaccines when health experts believed that the country was “turning the tide on the pandemic.”

Serum CEO Adar Poonawalla said that the government extended support to many countries when they were facing an acute crisis.(HT photo)
Serum CEO Adar Poonawalla said that the government extended support to many countries when they were facing an acute crisis.(HT photo)
Published on May 18, 2021 08:35 PM IST

The Taste with Vir Sanghvi: The dream of a modern India is dying

In this week's The Taste, Vir Sanghvi writes, "Such is the despondency over our politicians that many people are now actively considering emigrating to other countries"

The Taste with Vir Sanghvi: The dream of a modern India is dying(Twitter/reuterspictures/dansiddiqui)
The Taste with Vir Sanghvi: The dream of a modern India is dying(Twitter/reuterspictures/dansiddiqui)
Updated on May 06, 2021 01:21 PM IST

Poonawallas turned down $1 billion offer from private equity firms

The Poonawalla family-owned firm turned down the offer by a consortium of private equity firm TPG Capital, Abu Dhabi’s ADQ and Saudi Arabia’s Public Investment Fund following differences over valuation

Adar Poonawalla, CEO of SII. The family was seeking a valuation of $10 billion for a newly created unit under which the commercial interests of all of SII’s upcoming vaccines was to be housed. HT photo
Adar Poonawalla, CEO of SII. The family was seeking a valuation of $10 billion for a newly created unit under which the commercial interests of all of SII’s upcoming vaccines was to be housed. HT photo
Updated on May 05, 2021 06:27 AM IST

UK PM announces new £1 bn trade deal with India

The package contains new Indian investments of more than £533 million that is expected to create more than 6,000 jobs in vital sectors such as health and technology.

Boris Johnson said: “Like every aspect of the UK-India relationship, the economic links between our countries make our people stronger and safer... Lindsey Parnaby/Pool via REUTERS(REUTERS)
Boris Johnson said: “Like every aspect of the UK-India relationship, the economic links between our countries make our people stronger and safer... Lindsey Parnaby/Pool via REUTERS(REUTERS)
Published on May 04, 2021 03:21 AM IST

Under pressure from powerful to give jabs: Adar Poonawalla

The pressure was what led him to fly to London to be with his wife and children, Poonawalla, 40, told British newspaper The Times in an interview

Adar Poonawalla indicated that the move to London was linked to business plans to expand vaccine manufacturing to countries outside India, including the UK.(Bloomberg)
Adar Poonawalla indicated that the move to London was linked to business plans to expand vaccine manufacturing to countries outside India, including the UK.(Bloomberg)
Updated on May 02, 2021 12:52 AM IST

'Everything falls on my shoulders': Adar Poonawalla on vaccine pressure in India

“I’m staying here (London) for an extended time because I don't want to go back to that situation. Everything falls on my shoulders but I can't do it alone...,” Poonawalla said.

The SII CEO told ‘The Times’ in an interview about receiving aggressive calls from some of the most powerful people in India, demanding supplies of Covishield -- the Oxford/AstraZeneca Covid-19 vaccine that the Serum Institute is producing in India.(Bloomberg)
The SII CEO told ‘The Times’ in an interview about receiving aggressive calls from some of the most powerful people in India, demanding supplies of Covishield -- the Oxford/AstraZeneca Covid-19 vaccine that the Serum Institute is producing in India.(Bloomberg)
Published on May 01, 2021 06:37 PM IST

Serum Institute CEO plans to start Covid-19 vaccine production abroad: Report

"There's going to be an announcement in the next few days," Serum Institute of India CEO Adar Poonawalla said.

Adar Poonawalla, chief executive officer (CEO) of the Serum Institute of India (Reuters File Photo )
Adar Poonawalla, chief executive officer (CEO) of the Serum Institute of India (Reuters File Photo )
Updated on May 01, 2021 06:05 AM IST

Short of doses, Delhi to keep expanded jabs drive on hold

Of the 13.4 million doses needed by the Capital, Delhi will get the first batch of 300,000 shots only by May 3 from Serum Institute of India (SII), which manufactures Covishield, the mainstay of India’s vaccination programme, senior officials aware of developments said.

A medical worker inoculates a woman with the Covaxin Covid-19 coronavirus vaccine, at a health centre in New Delhi on April 29. (AFP)
A medical worker inoculates a woman with the Covaxin Covid-19 coronavirus vaccine, at a health centre in New Delhi on April 29. (AFP)
Published on Apr 30, 2021 04:05 AM IST

SII reduces vaccine price for state govts

SII, which manufactures the vaccine developed by Oxford University and British drug firm AstraZeneca, had last week announced a price of ₹400 for states and ₹600 for private hospitals to purchase jabs for the third phase.

A nurse holds a vial of AstraZeneca Covid-19 vaccine manufactured by the Serum Institute of India.(AP)
A nurse holds a vial of AstraZeneca Covid-19 vaccine manufactured by the Serum Institute of India.(AP)
Published on Apr 29, 2021 02:34 AM IST

'We remember India's generosity': US vows to deliver vaccine resources

"What we are doing is diverting our own order of our own supplies to the Serum Institute for their manufacturing," a senior administration official said, elaborating on the exact nature of the assistance that the US is providing to India in view of the recent Covid-19 surge.

President Joe Biden speaks about Covid-19 vaccinations at the White House, in Washington. (File Photo / AP)
President Joe Biden speaks about Covid-19 vaccinations at the White House, in Washington. (File Photo / AP)
Published on Apr 27, 2021 01:23 PM IST

India's close allies US, UAE and Saudi Arabia step forward in Covid fight

While National Security Advisor Ajit Doval spoke to his US counterpart Jake Sullivan, Saudi and UAE royals, foreign minister Jaishankar has been in constant touch with Secretary of State Anthony Blinken and his European counterparts for bridging the health infrastructural gap in India.

India’s national security advisor Ajit Doval spoke to his US counterpart Jake Sullivan on the phone on Sunday
India’s national security advisor Ajit Doval spoke to his US counterpart Jake Sullivan on the phone on Sunday
Published on Apr 26, 2021 08:54 AM IST

Bharat Biotech seeks DCGI's nod to extend shelf life of Covaxin

In support of their proposal, Bharat Biotech has submitted updated accelerated and real-time stability data of Coaxin along with the justification for the extension of shelf-life.

The DCGI had extended the shelf-life of Covishield from six to nine months from its manufacturing date in February.(Bloomberg)
The DCGI had extended the shelf-life of Covishield from six to nine months from its manufacturing date in February.(Bloomberg)
Published on Apr 25, 2021 04:45 PM IST

Adar Poonawalla has assured 'maximum support': CMO Maharashtra on vaccination

Maharashtra is the worst-hit state in the country with 6,94,480 active cases of the coronavirus disease (Covid-19).

Maharashtra chief minister Uddhav Thackeray(Satish Bate/Hindustan Times)
Maharashtra chief minister Uddhav Thackeray(Satish Bate/Hindustan Times)
Published on Apr 25, 2021 09:05 AM IST

‘Covishield most affordable Covid-19 jab’: SII calls out ‘inaccurate comparison’

SII’s statement comes against the backdrop of flak it faced after it notified on Wednesday that it will sell one jab of this two-dose Covid-19 vaccine for ₹600 to private facilities and ₹400 to state governments.

Adar Poonawalla, chief executive officer of Serum Institute of India issued a clarification on Saturday over the price of its Covid-19 vaccine.(Bloomberg)
Adar Poonawalla, chief executive officer of Serum Institute of India issued a clarification on Saturday over the price of its Covid-19 vaccine.(Bloomberg)
Published on Apr 24, 2021 06:25 PM IST
SHARE
  • 1
  • 2
  • 3
  • ...
Story Saved
×
Saved Articles
Following
My Reads
My Offers
Sign out
New Delhi 0C
Friday, December 02, 2022
Start 15 Days Free Trial Subscribe Now
Register Free and get Exciting Deals